InsideViews offer a window into the practices and priorities of research-based organizations. Short, accessible yet informative Q&A articles — created in collaboration with Nature’s writers — reveal the people whose products, services or institutional visions are influencing science, technology and innovation today.
Timothy O'Brien, Clinical Associate Professor in Restorative Dentistry and Programme Lead in Periodontology at Peninsula Dental School at the University of Plymouth, discusses the courses that they offer and what makes Plymouth different from other dental schools
Christoph Hergersberg, vice president of R&D for Thermo Fisher Scientific’s Protein and Cell Analysis and Antibody and Immunoassay businesses, explains how the Invitrogen iBright Imaging Systems can dramatically simplify and improve the protein visualization process.
Professor Rebekah Brown director of the Monash Sustainable Development Institute outlines how the university is tackling global challenges embodied by the United Nations' Sustainable Development Goals and implementing solutions to real-world problems through partnerships.
Nature Index 2018 Earth and Environmental Sciences
(28 June 2018)
Dr. Daniella Steel, Senior product manager at Horizon Discovery Ltd, discusses how Horizon has created a library of ready-made isogenic human cell line pairs edited using CRISPR-Cas9 technology, and what makes the library different.
Elizabeth Croft, Dean of Engineering at Monash University in Melbourne, Australia, discusses the large-scale collaborative research projects that she has led looking into robots working alongside people.
Dr. Benedict Cross, R&D Manager, Functional Genomic Screening at Horizon Discovery Ltd discusses how they have optimized more than 50 cell lines for CRISPR screening and how Horizon supports their customers.
Nazafarin Lahoutifard, Director of Portfolio Management for the HPLC Business at Gilson, explains how recent advances in the pumps that drive chromatographic analysis are allowing unprecedented purification and consistency.
Yosuke Hiraoka, principal research scientist at Nitta Gelatin Inc, Japan, discusses what sets the company apart from other collagen and gelatin makers and how they have evolved to meet changing demands.
Ignacio Sánchez, president at Pontificia Universidad Católica de Chile (PUC) explains why the university is both a Latin American gateway for collaboration and a player in several international collaborations.
Calum Drummond, Deputy Vice-Chancellor at RMIT University discusses what research and innovation means to the university. Eight RMIT directors also discuss how they are using the university's expertise to address real-world challenges.
Edward Cheng, Corporate Vice President of Tencent, discusses his expectations for the WE summit and Tencent’s ambition to address global challenges with technology. Find out more at: http://we.tencent.com
Tetsuo Endoh, director of the Center for Innovative Integrated Electronic Systems (CIES) and professor at the Graduate School of Engineering, Tohoku University, discusses why collaborations are so important between academia, industry and government.
Dr. Thorsten Kues, Solutions Manager at ZEISS discusses the launch of ZEISS Celldiscoverer 7, their fully automated microscope and how it will help them to produce data quickly, without compromising on image quality.
Allison Paradise, executive director of My Green Lab, explains how labs could be operating more efficiently be implementing simple cold-storage management best practices and what led to the launch of the first North American Laboratory Freezer Challenge.
Professor Mark Ferguson Director-General of Science Foundation Ireland and Chief Scientific Adviser to the Government of Ireland, discusses what he believes makes Ireland a destination for researchers and what’s next for research in Ireland
Basel-born Professor Martin Fussenegger discusses why he believes scientists should come and live and work in Basel and why Basel offers many exciting opportunities for innovation and career development
Robert Abraham, Senior Vice President and Group Head of Oncology Research and Development at Pfizer, discusses their postdoc programme and its aim to train and prepare the next generation of innovative scientists.
Peter Keegans, CEO and Ravi Rattan clinical director, discuss the Jacobs Holdings acquisition means for Southern Dental’s dentists, and for the company’s plan to become the largest dental provider in England’s southeast within five years.
Bernd Huber, LMU’s president, discusses the university's plans and how they set out to recruit foreign researchers, at all career levels, by introducing a number of programmes designed to attract them to Munich.
Dr. Natasha Barteneva, director of Boston Children’s Hospital’s Flow & Imaging Cytometry Resource, lecturer at Harvard Medical School and adjunct professor at Nazarbayev University, describes why the Amnis ImageStream system from MilliporeSigma is so integral to her research.
Dr Aaron Elliott, CEO of Ambry Genetics, discusses the popularity of genetic testing, and thinks genetic counsellors, clinicians, and the public, need to know how they can get the most reliable results.
Ole Petter Ottersen, professor of medicine at the University of Oslo, and Liselotte Hoejgaard, professor of medicine and technology at the University of Copenhagen, chair and member of the Olav Thon Foundation’s science advisory board, discuss the Olav Thon Foundation's award and how the nomination process works.
James Murray, immunoassay product development scientist at Abcam discusses Abcam’s vision when they acquired MitoSciences and the speed at which they can bring high quality, novel kits to the market as a result.
Klemen Zupančič, Chief executive officer of sciNote, discusses what makes his platform unique, and why sciNote is teaming up with Gilson, a leading instruments company, to make research more robust, verifiable and reproducible.
Peter Schulz-Knappe, Chief scientific officer at Protagen AG, discusses what attracted him to Luminex and the differences that using FLEXMAP 3D has made to creating assays to support the development of drugs and companion diagnostics at Protagen.
Aaron Elliott, CEO of Ambry Genetics, discusses the barriers that they are facing to providing innovative change in healthcare. Here, Aaron outlines how he believes all parties can move forward together to advance treatments and ultimately find cures.
Dr. Alwaleed Alkhaja, senior editor at Hamad Bin Khalifa University Press, discusses its worldclass publishing house and QScience.com, an online, open access, academic publishing platform, to support the academic research output of researchers in Qatar and the Middle East.
Ding Zhongli, a geoscience expert with a long-term career at the Chinese Academy of Sciences (CAS) and who leads the University of Chinese Academy of Sciences, outlines his plans to leverage the abundant research resources of CAS to develop a world-class research university.
Zhen Liang, PhD, assistant president, Harbin Institute of Technology (HIT) and executive vice director of the preparation office for Harbin Institute of Technology, Shenzhen (HITSZ) discusses the creation of HITSZ and outlines their plans for the future.
Dushyant Pathak, Associate Vice Chancellor for Technology Management & Corporate Relations, and Executive Director of Venture Catalyst at the University of California, Davis discusses how the university is driving innovation and technology commercialization.
Caroline Whitacre, Senior Vice President for Research at The Ohio State University discusses the leadership role that the univerisity is taking to solve some of the global challenges of the 21st century. Caroline talks about the initiative, its accomplishments, and the hiring effort behind it.
Dr. Garik Israelian, founder of STARMUS and researcher at the Canary Islands Institute of Astrophysics, discusses this year’s festival in Norway, how the festival started, and why is it a major opportunity for science communication.
Dr. Aaron Elliott, CEO of Ambry Genetics, discusses AmbryShare, a compilation of Exome sequencing data from more than 11,000 hereditary breast and ovarian cancer patients and why they’re opening their dataset to anyone with an interest in studying it.
Michael Weiner, Vice President of Molecular Sciences at Abcam, discusses the approach Abcam are using to produce recombinant antibodies and how the company’s technology portfolio can raise reproducibility standards for the entire field.
Dr. Charles Nicolette, Chief Scientific Officer and Vice President of Research and Development, discusses how Argos Therapeutics is developing individualised, precision cell therapies that are designed to train the body’s immune system, so that patients can fight their own diseases.
Dr. Louis Yuge, Professor at Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan, talks about the development of Gravite®, a device that enables researchers to conduct unprecedented experiments in microgravity and hypergravity conditions.
Dr. Núria Godessart, Head of Skin Biology and Pharmacology at R&D in Almirall, discusses the company's changing focus on dermatology and approach to external collaborations, and what these changes mean for the company, its researchers, and its partners.
Dr. Aleix Prat, head of medical oncology at the Hospital Clinic in Barcelona and the scientific committee coordinator for SOLTI, discusses why international collaborations are needed to make progress in the treatment of breast cancer and SOLTI's role in coordinating multi-institutional breast cancer trials.
Dr Josep Rodiera, a MD and PhD, anesthesiologist, with a master’s degree in bioengineering, heads the anesthesiology department at Centro Médico Teknon, a leading private hospital in Barcelona, Spain, and part of the Quirónsalud medical group Fresenius-Helios. Here he discusses the department's goal of achieving personalized, safer care, and transforming the practice of anesthesiology.
Edmond Magner, Dean of the Faculty of Science & Engineering at the University of Limerick, discusses how the Bernal Institute aims to achieve its goal: building a global reputation in applied sciences and engineering.
Brandy Matthews, MD, Senior Medical Advisor, Alzheimer’s Disease Team at Lilly, explains why the company remains so dedicated to finding treatments that halt the progression of Alzheimer’s and reduce its burden on patients, caregivers and society.
Wei Huang, president of NanjingTech and member of the Chinese Academy of Sciences, shares his plan to build a world-class university by boosting Nanjing Tech University's research and expanding its scope.
At Japan’s Gunma University, a one-of-a-kind graduate program provides opportunities for students to learn about heavy ion cancer treatments amid a supportive community of medical scientists. Here, Takashi Nakano talks about the advantages of heavy ion therapeutics and welcomes enquiries from prospective applicants interested in playing an active role on the global stage.
In 2015, Olam awarded the inaugural Prize for Innovation in Food Security to Professor Norman Uphoff and the SRI International Network and Resources Center (SRI-Rice) at Cornell University. Here, Professor Uphoff, former director of the Cornell International Institute for Food, Agriculture, and Development, discusses SRI-Rice, which was founded in 2010 to support further development and dissemination of the System of Rice Intensification (SRI) synthesized in Madagascar over 30 years ago
Dr. Daniel Weinberger, Director and Chief Executive Officer of the Johns Hopkinsaffiliated non-profit, explains how Connie Lieber’s vision continues to shape the institute’s unique approach to psychiatric research. The institute is now accepting nominations for the Constance Lieber Prize for Innovation in Developmental Neuroscience, a new $100,000 prize that will be awarded in June of 2017.
Sanjay Keswani, senior vice president and global head of Neuroscience, Ophthalmology and Rare Diseases, Roche Pharma Researc, discusses the future of R&D efforts in psychiatry, with the aim of reducing cognitive impairment and negative symptoms associated with schizophrenia, and explains how the seemingly disparate parts of neuroscience, ophthalmology and rare diseases fit together.
Calum Drummond, RMIT’s Deputy Vice-Chancellor of Research and Innovation and Vice President, discusses Enabling Capability Platforms (ECPs), a refined model for universities to innovate, help to unlock value, and, ultimately, become more engaged and relevant to the world beyond academia.
Julian Symons, vice president, Disease Area R&D leader, discusses the work his team is doing to advance toward their objective: free every person from the burden of the infection of respiratory syncytial virus (RSV).
Brian Bilecki, Director of Vivarium Design Services at Allentown Inc., speaks about the advantages of exhaust air dust (EAD) protocols for colony health monitoring and the benefits of the Sentinel EAD system
The Liliane Bettencourt Prize for Life Sciences, awarded annually by the Bettencourt Schueller Foundation, aims to honour the work of a European researcher aged 45 years and younger who is involved in promising or innovative research.
Chief Scientific Officer Roberto Polakiewicz discusses how Cell Signaling Technology rigorously tests all of its products in-house and then works with life scientists around the world to help make their experiments more consistent and reliable.
Vice President of Drug Discovery Biology Peter Smith speaks about some of the most exciting developments in cancer genomics-based therapies and the unique power of H3 Biomedicine’s drug discovery platform.
Lawrence Blatt, who co-leads the Infectious Diseases & Vaccines Therapeutic Area at Janssen, talks about how the company is working to discover and develop transformational therapies to counter these threats
Johan Van Hoof, M.D., Global Therapeutic Head, Infectious Diseases and Vaccines, discusses the importance of vaccines and the technologies his company has deployed to address some of the most challenging infectious diseases.
Kathleen E. McGrath of the University of Rochester Medical School talks about how EMD Millipore’s Amnis brand ImageStream has given her insights into the haematopoiesis of platelets, red blood cells and lymphocytes
Michel Goldman, field chief editor of Frontiers in Medicine, explains why scientists seeking to improve patients’ lives must think beyond the science and outlines the goals of the Institute for Interdisciplinary Innovation in health care.
Richard Connell, vice-president and worldwide head of external research solutions, Pfizer Global Research and Development, speaks about Pfizer’s new partnership with Sigma-Aldrich, and what it means for the research community.
Michael Seiler, associate director of product management, immune system models and GEMS-design at Taconic Biosciences, speaks about the company’s new mouse model for oncological and immunological research.
Xijun Wang, general director of the National TCM Key Lab of Serum Pharmacochemistry at Heilongjiang University of Chinese Medicine, talkse about the links he is building between traditional and contemporary medicine in China.
Amar Thyagarajan, senior product manager for the neuroscience portfolio at Taconic, discusses the importance of developing mouse models, and how he works closely with his customers to solve scientific challenges.